Jinpeng Li

Jinan, 250117, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Determinants of Fear of Cancer Recurrence and Development of a Nomogram-Based Risk Prediction Model in Patients with Primary Liver Cancer: A Single-Center Cross-Sectional Study.

Determinants of Fear of Cancer Recurrence and Development of a Nomogram-Based Risk Prediction Model in Patients with Primary Liver Cancer: A Single-Center Cross-Sectional Study.

Journal: Journal of hepatocellular carcinoma

Published: March 26, 2026

A generalized two-step floating building catchment area model for measuring EMS accessibility with in-building patient access.

A generalized two-step floating building catchment area model for measuring EMS accessibility with in-building patient access.

Journal: BMC health services research

Published: March 24, 2026

Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy.

Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy.

Journal: Journal of hepatocellular carcinoma

Published: February 14, 2026

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Journal: Frontiers in immunology

Published: August 06, 2025

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Journal: Frontiers in immunology

Published: June 08, 2025

Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multicenter, case-control study.

Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multicenter, case-control study.

Journal: Frontiers in immunology

Published: June 02, 2025

Efficacy and liver function preservation with donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An ALBI grade analysis.

Efficacy and liver function preservation with donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An ALBI grade analysis.

Journal: Frontiers in oncology

Published: April 15, 2025

Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative HCC management.

Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative HCC management.

Journal: Hepatology (Baltimore, Md.)

Published: February 05, 2025

Letter to the Editor: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.

Letter to the Editor: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: November 09, 2024

Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Journal: Hepatology (Baltimore, Md.)

Published: October 27, 2024

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma.

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: September 04, 2024

Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

Journal: Journal of hepatocellular carcinoma

Published: May 07, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026